Novabay Pharmaceuticals (NBY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Sales | 2,339 | 3,643 | 3,826 | 3,662 | 3,273 |
| Cost of Goods | 739 | 1,889 | 1,451 | 1,824 | 1,459 |
| Gross Profit | 1,600 | 1,754 | 2,375 | 1,838 | 1,814 |
| Operating Expenses | 3,684 | 12,069 | 3,283 | 4,814 | 4,655 |
| Operating Income | -1,345 | -9,426 | -457 | -2,152 | -2,382 |
| Other Income | 0 | 1,220 | 321 | -3 | 2,271 |
| Pre-tax Income | -1,345 | -8,206 | -136 | -2,155 | -111 |
| Net Income Continuous | -1,345 | -8,206 | -136 | -2,155 | -111 |
| Net Income Discontinuous | -394 | N/A | N/A | N/A | N/A |
| Net Income | $-1,739 | $-8,206 | $-136 | $-2,155 | $-111 |
| EPS Basic Total Ops | -29.72 | -174.13 | -126.22 | -50.00 | -2.80 |
| EPS Basic Continuous Ops | -23.11 | -174.70 | -2.96 | -50.00 | -2.71 |
| EPS Basic Discontinuous Ops | -6.77 | N/A | N/A | N/A | N/A |
| EPS Diluted Total Ops | -29.72 | -174.13 | -126.22 | -50.00 | -2.80 |
| EPS Diluted Continuous Ops | -23.11 | -174.70 | -2.96 | -50.00 | -2.71 |
| EPS Diluted Discontinuous Ops | -6.77 | N/A | N/A | N/A | N/A |
| EBITDA(a) | $-1,332 | $-2,566 | $-338 | $-2,032 | $-2,261 |